S. 832In Committee
EPIC Act of 2025
Extends the market approval period required for certain drug products to qualify for Medicare drug price negotiation, aligning them with biologics beginning in 2028
Plain-English overview
What this bill does
Extends the market approval period required for certain drug products to qualify for Medicare drug price negotiation, aligning them with biologics beginning in 2028
Key points
- Amend Medicare drug negotiation eligibility
- Extend drug approval timeline
Current status
Where it stands
Status
In Committee
Latest action
2025-03-04 — Read twice and referred to the Committee on Finance.
Related context
Topics and policy areas
undefinedHealth